HBW Insight is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Nicotine Replacement Therapy Prop 65 Warning Unfounded, FDA Tells Court

This article was originally published in The Tan Sheet

Executive Summary

A California appellate court's ruling that a Prop 65 warning for nicotine replacement therapies is not federally preempted would require product manufacturers to use warning language FDA has determined lacks scientific support, the agency says
Advertisement

Related Content

NRT Firms’ Deference To “Informal” FDA Letters In Prop 65 Case Improper
NRT Firms’ Deference To “Informal” FDA Letters In Prop 65 Case Improper
NRT Firms’ Deference To “Informal” FDA Letters In Prop 65 Case Improper
FDA Prop 65 NRT Warning Rejection Should Be Given Deference, Firms Say
FDA Prop 65 NRT Warning Rejection Should Be Given Deference, Firms Say
FDA Prop 65 NRT Warning Rejection Should Be Given Deference, Firms Say
NRT & Prop 65
Prop 65 Smoking Cessation Warnings Not In Conflict With FDA Rules – Court
Prop 65 Smoking Cessation Warnings Not In Conflict With FDA Rules – Court
Smoking Cessation Pregnancy Data Required For Alternative Warning Use

Topics

Advertisement
UsernamePublicRestriction

Register

PS094561

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel